HUP0300596A3 - Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it - Google Patents

Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it

Info

Publication number
HUP0300596A3
HUP0300596A3 HU0300596A HUP0300596A HUP0300596A3 HU P0300596 A3 HUP0300596 A3 HU P0300596A3 HU 0300596 A HU0300596 A HU 0300596A HU P0300596 A HUP0300596 A HU P0300596A HU P0300596 A3 HUP0300596 A3 HU P0300596A3
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
torasemide modification
amorphous torasemide
Prior art date
Application number
HU0300596A
Other languages
English (en)
Original Assignee
Pliva D D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D D filed Critical Pliva D D
Publication of HUP0300596A2 publication Critical patent/HUP0300596A2/hu
Publication of HUP0300596A3 publication Critical patent/HUP0300596A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
HU0300596A 2000-03-20 2000-05-02 Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it HUP0300596A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification

Publications (2)

Publication Number Publication Date
HUP0300596A2 HUP0300596A2 (hu) 2003-07-28
HUP0300596A3 true HUP0300596A3 (en) 2005-08-29

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300596A HUP0300596A3 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it

Country Status (29)

Country Link
US (1) US6767917B1 (hu)
EP (1) EP1272470B1 (hu)
JP (1) JP2003528083A (hu)
KR (1) KR20020093847A (hu)
CN (1) CN1211368C (hu)
AR (1) AR023788A1 (hu)
AT (1) ATE256662T1 (hu)
AU (1) AU2000241348A1 (hu)
BG (1) BG107208A (hu)
BR (1) BR0017175A (hu)
CA (1) CA2401908A1 (hu)
CZ (1) CZ20023436A3 (hu)
DE (1) DE60007360T2 (hu)
EA (1) EA004950B1 (hu)
EE (1) EE200200534A (hu)
ES (1) ES2213006T3 (hu)
GE (1) GEP20043300B (hu)
HR (1) HRP20000162B1 (hu)
HU (1) HUP0300596A3 (hu)
IL (1) IL151801A0 (hu)
IS (1) IS6551A (hu)
MX (1) MXPA02009210A (hu)
NO (1) NO20024464L (hu)
PL (1) PL357154A1 (hu)
PT (1) PT1272470E (hu)
SK (1) SK15092002A3 (hu)
WO (1) WO2001070694A1 (hu)
YU (1) YU70502A (hu)
ZA (1) ZA200208309B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465496B1 (en) * 1999-08-11 2002-10-15 Teva Pharmaceutical Industries, Ltd. Torsemide polymorphs
IN192178B (hu) 2001-08-03 2004-03-06 Ranbaxy Lab
CA2536967A1 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
JP2008531579A (ja) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強利尿化合物、組成物および使用方法
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
US6096779A (en) * 1995-02-22 2000-08-01 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
IN182496B (hu) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6465496B1 (en) 1999-08-11 2002-10-15 Teva Pharmaceutical Industries, Ltd. Torsemide polymorphs

Also Published As

Publication number Publication date
DE60007360D1 (de) 2004-01-29
KR20020093847A (ko) 2002-12-16
IL151801A0 (en) 2003-04-10
PL357154A1 (en) 2004-07-12
EE200200534A (et) 2004-04-15
IS6551A (is) 2002-09-17
CN1452613A (zh) 2003-10-29
US6767917B1 (en) 2004-07-27
EA004950B1 (ru) 2004-10-28
JP2003528083A (ja) 2003-09-24
EP1272470B1 (en) 2003-12-17
PT1272470E (pt) 2004-05-31
CA2401908A1 (en) 2001-09-27
HUP0300596A2 (hu) 2003-07-28
WO2001070694A1 (en) 2001-09-27
ES2213006T3 (es) 2004-08-16
YU70502A (sh) 2006-01-16
EA200201003A1 (ru) 2003-02-27
ZA200208309B (en) 2003-10-15
GEP20043300B (en) 2004-02-10
ATE256662T1 (de) 2004-01-15
AR023788A1 (es) 2002-09-04
HRP20000162A2 (en) 2001-12-31
MXPA02009210A (es) 2004-09-06
WO2001070694A8 (en) 2002-03-21
EP1272470A1 (en) 2003-01-08
CZ20023436A3 (cs) 2003-03-12
SK15092002A3 (sk) 2003-05-02
HRP20000162B1 (en) 2004-06-30
AU2000241348A1 (en) 2001-10-03
DE60007360T2 (de) 2004-10-07
BR0017175A (pt) 2002-12-10
NO20024464L (no) 2002-09-20
BG107208A (en) 2003-07-31
CN1211368C (zh) 2005-07-20
NO20024464D0 (no) 2002-09-18

Similar Documents

Publication Publication Date Title
HUP0301069A3 (en) Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301187A3 (en) Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0300731A3 (en) Valsartan salts, process for their preparation and pharmaceutical compositions thereof
HUP0300894A3 (en) Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
HUP0700086A2 (en) 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0303524A3 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
MXPA03004402A (es) Composicion mejorada de sucralosa y procedimiento para su preparacion.
HUP0302480A3 (en) Pyridinone derivatives for treatment of atherosclerosis, process for preparation thereof and pharmaceutical compositions containing the same
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0301817A3 (en) Kahalalide compounds, process for preparing thereof, pharmaceutical compositions comprising them and their use
HUP0302130A3 (en) Combination pharmaceutical compositions and process for their preparation
IL154096A0 (en) Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
HUP0204202A3 (en) Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it
HUP0100489A3 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0302515A3 (en) Sulfanidothienopyrimidines, process for their preparation and pharmaceutical compositions containing them
HUP0204394A3 (en) Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0302429A3 (en) 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use
HUP0303105A3 (en) Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees